Academic Content and Language Evaluation of This Article
Academic Rules and Norms of This Article
Citation of this article
Corresponding Author of This Article
Research Domain of This Article
Article-Type of This Article
Open-Access Policy of This Article
Times Cited Counts in Google of This Article
Number of Hits and Downloads for This Article
- Total Article Views (8266)
All Articles published online
|
Featured Article
|
Publishing Process of This Article
|
Jan 24, 2022 (publication date) through Nov 9, 2024
Times Cited of This Article
Journal Information of This Article
Publication Name
World Journal of Clinical Oncology
ISSN
2218-4333
Publisher of This Article
Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA
| For: | Pitoia F, Jerkovich F, Trimboli P, Smulever A. New approaches for patients with advanced radioiodine-refractory thyroid cancer. World J Clin Oncol 2022; 13(1): 9-27 [PMID: 35116229 DOI: 10.5306/wjco.v13.i1.9] |
|---|---|
| URL: | https://www.wjgnet.com/2218-4333/full/v13/i1/9.htm |
| Number | Citing Articles |
| 1 |
Yujia Liu, Jiafeng Wang, Xiaoping Hu, Zongfu Pan, Tong Xu, Jiajie Xu, Liehao Jiang, Ping Huang, Yiwen Zhang, Minghua Ge. Radioiodine therapy in advanced differentiated thyroid cancer: Resistance and overcoming strategy. Drug Resistance Updates 2023; 68: 100939 doi: 10.1016/j.drup.2023.100939
|
| 2 |
Luca Sessa, Carmela De Crea, Nikolaos Voloudakis, Francesco Pennestri’, Luca Revelli, Pierpaolo Gallucci, Germano Perotti, Luca Tagliaferri, Ernesto Rossi, Esther Diana Rossi, Alfredo Pontecorvi, Rocco Bellantone, Marco Raffaelli. Single Institution Experience in the Management of Locally Advanced (pT4) Differentiated Thyroid Carcinomas. Annals of Surgical Oncology 2024; 31(9): 5515 doi: 10.1245/s10434-024-15356-z
|
| 3 |
Francis Worden, Olivera Rajkovic-Hooley, Neil Reynolds, Gary Milligan, Jingchuan Zhang. Real-world treatment patterns and clinical outcomes in patients with radioiodine-refractory differentiated thyroid cancer (RAI-R DTC) treated with first line lenvatinib monotherapy in the United States. Endocrine 2023; 84(2): 663 doi: 10.1007/s12020-023-03638-7
|
| 4 |
Fabian Pitoia, Rafael Selbach Scheffel, Ines Califano, Alicia Gauna, Hernán Tala, Fernanda Vaisman, Alejandro Roman Gonzalez, Ana Oliveira Hoff, Ana Luiza Maia. Management of radioiodine refractory differentiated thyroid cancer: the Latin American perspective. Reviews in Endocrine and Metabolic Disorders 2024; 25(1): 109 doi: 10.1007/s11154-023-09818-0
|
| 5 |
Daisy Carolina Buenaventura, Hernando Vargas-Sierra, Natalia Aristizabal-Henao, Jose Luis Torres-Grajales, Carolina Aguilar-Londono, Johnayro Gutierrez-Restrepo. Posterior Reversible Encephalopathy Syndrome as an Adverse Effect of Lenvatinib in a Patient with Papillary Thyroid Carcinoma: A Case Report. International Journal of Endocrinology and Metabolism 2023; 21(3) doi: 10.5812/ijem-136900
|
| 6 |
Fernando Jerkovich, Soledad Capalbo, Erika Abelleira, Fabián Pitoia. Ten years’ real-life experience on the use of multikinase inhibitors in patients with advanced differentiated thyroid cancer. Endocrine 2024; 85(2): 817 doi: 10.1007/s12020-024-03867-4
|
| 7 |
E. Abou Jokh Casas, A. Repetto, A. Rodriguez Gasén, J.L. Vercher Conejero, P. Bello Arques, T. Cambil Molina, J.A. Vallejo Casas. Update on iodine-refractory differentiated thyroid carcinoma. Revista Española de Medicina Nuclear e Imagen Molecular (English Edition) 2023; 42(5): 325 doi: 10.1016/j.remnie.2023.07.003
|
| 8 |
E. Abou Jokh Casas, A. Repetto, A. Rodríguez Gasén, J.L. Vercher Conejero, P. Bello Arques, T. Cambil Molina, J.A. Vallejo Casas. Actualización en carcinoma diferenciado de tiroides refractario a radioyodo. Revista Española de Medicina Nuclear e Imagen Molecular 2023; 42(5): 324 doi: 10.1016/j.remn.2023.06.005
|
| 9 |
Giusy Elia, Armando Patrizio, Francesca Ragusa, Sabrina Rosaria Paparo, Valeria Mazzi, Eugenia Balestri, Chiara Botrini, Licia Rugani, Salvatore Benvenga, Gabriele Materazzi, Claudio Spinelli, Alessandro Antonelli, Poupak Fallahi, Silvia Martina Ferrari. Molecular features of aggressive thyroid cancer. Frontiers in Oncology 2022; 12 doi: 10.3389/fonc.2022.1099280
|
| 10 |
Silvia Martina Ferrari, Armando Patrizio, Giulio Stoppini, Giusy Elia, Francesca Ragusa, Eugenia Balestri, Chiara Botrini, Licia Rugani, Emilio Barozzi, Valeria Mazzi, Concettina La Motta, Alessandro Antonelli, Poupak Fallahi. Recent advances in the use of tyrosine kinase inhibitors against thyroid cancer. Expert Opinion on Pharmacotherapy 2024; 25(12): 1667 doi: 10.1080/14656566.2024.2393281
|
| 11 |
Maria Boudina, Eleana Zisimopoulou, Persefoni Xirou, Alexandra Chrisoulidou. Aggressive Types of Malignant Thyroid Neoplasms. Journal of Clinical Medicine 2024; 13(20): 6119 doi: 10.3390/jcm13206119
|